As part of the pioneers of pharmaceutical technology in India, the Dadachanji Group of Companies trusted for over 30 years, Kaisha Lifesciences is a young and innovative pharmaceutical company that strives to bring safe, high-quality, and highly effective medication to patients worldwide along with improving the ease and efficiency by which healthcare workers administer their products.
Apart from offering its own range of products, Kaisha Lifesciences is engaged in providing contract R&D services to customers, from product development to scale up.
"You may not know us, but we have been by your side for over 30 years"Know More
Vaccine manufacturers and ancillaries are anticipating a strong demand from the government for Covid-19 vaccines alone after the government announced its plans to procure ₹35,000 crore worth of jabs, an amount estimated to be enough to vaccinate roughly half of the country's population.
February 21, 2021
Indian drug vial maker Schott Kaisha is expecting annual vial sales for COVID-19 shots to more than triple as vaccine production, including by one of its top customers Serum Institute, increases in response to a monster second wave of infections.
May 20, 2021
But navigating this ebb and flow in demand are a bunch of rather low-profile companies that supply the medicines on their own or through alliances with larger drug- or vaccine-makers. And it's not been an easy ride, as the fortunes of these medicines fluctuate with every advisory from the Government either recommending a drug for Covid-19 treatment or dropping it entirely from the list.
June 13, 2021
Vaccine major Serum Institute of India has acquired 50 per cent stake in pharma packaging firm Schott Kaisha to become a joint venture partner of Germany's specialty glass company Schott AG. Serum Institute has acquired stake from former co-owners Kairus Dadachanji and Shapoor Mistry, Schott and Serum Institute of India said in a joint statement.
August 17, 2021